Daily transcranial pulsed electromagnetic field (T-PEMF) therapy for Parkinson's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will compare daily 30-minute T-PEMF treatment against a sham (placebo) over 6 and 12 months to measure effects on neuro-mechanical and molecular biological markers and on medication needs. Outcomes in participants will be compared with the disorder's natural progression and with a healthy reference group. Eligible participants are people with idiopathic Parkinson's disease in Hoehn & Yahr stage 1–2 with preserved cognition (MMSE > 22) and without contraindications such as active implants, epilepsy, or anticoagulant use. The protocol includes careful monitoring of motor function and biological measures, with the goal of tracking changes over time versus placebo.

Why it matters

Who can join: the full rules

Intervention Groups

Inclusion Criteria:

* Diagnosed with idiopathic Parkinson's disease
* The participant must be able to understand, accept, and complete the planned procedures
* Parkinson's symptoms in the medicated state must correspond to Hoehn \& Yahr stage 1 or 2
* Mini Mental-State Examination score \> 22

Exclusion Criteria:

* Cancer in the brain, neck, or head area
* Presence of active medical implants
* Epilepsy
* Alcoholism
* Substance abuse
* Open wound on the scalp
* Severe psychopathological disorders
* Pregnancy
* Changes in pharmacological anti-Parkinson medication within the last 6 weeks prior to the start of T-PEMF treatment
* Anticoagulant treatment with Marevan, Marcoumar, Pradaxa, Eliquis, Xarelto, Lixiana, Novostan, Fragmin, or Innohep
* Neurological disease other than Parkinson's disease
* Previous stroke
* Reduced motor function caused by conditions other than Parkinson's disease

Control Group with Parkinson's Disease

Inclusion Criteria:

* Diagnosed with idiopathic Parkinson's disease
* The patient must be able to understand, accept, and complete the planned procedures
* Parkinson's symptoms in the medicated state must correspond to Hoehn \& Yahr stage 1 or 2
* Mini Mental-State Examination score \> 22

Exclusion Criteria:

* Neurological disease other than Parkinson's disease
* Reduced motor function caused by conditions other than Parkinson's disease

Healthy Reference Group:

Inclusion Criteria:

-The patient must be able to understand, accept, and complete the planned procedures

Exclusion Criteria:

* Neurological disease
* Reduced motor function caused by condition

Where it's running

• Odense University Hospital
  Odense, Denmark Recruiting
• University of Southern Denmark
  Odense, Denmark Recruiting

Study contacts

• Principal investigator: Anne Sofie Bøgh Malling, Ph.d. — University of Southern Denmark
• Study coordinator: Anne Sofie Bøgh Malling, Ph.d.
• Email: amalling@health.sdu.dk
• Phone: +45 28903733

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• UX-DA003 injections for Parkinson's disease

  This early-phase trial tests whether injecting UX-DA003 is safe and may help motor symptoms in people with Parkinson's whose response to standard treatments has declined.

  Recruiting Early Phase 1 The First Affiliated Hospital of Anhui Medical University · Hefei, Anhui · NCT07911670

• Strength and dual-task training to help people with Parkinson’s improve strength and function

  This trial tests three levels of physiotherapy, including progressive resistance training with and without cognitive dual-task and instability components, to see if they improve muscle strength, body composition, and physical function in adults with Parkinson’s or related syndromes.

  Recruiting University of Valencia · Valencia, Valencia · NCT07907302

• Spinal Mobility, Rigidity, and Kinesiophobia in Parkinson's Disease with and without TMD

  This study tests whether people with Parkinson's disease who have Temporomandibular Disorders differ in spinal mobility, axial rigidity, and kinesiophobia from those without TMD.

  Recruiting Mustafa Kemal University · Hatay · NCT07850674

• A 12-Week Trial of Flexilev with the OraFID Device and App for Parkinson's

  This study tests whether taking small, precise doses of Flexilev with the OraFID dosing device and Levilog app is acceptable and helps people with Parkinson's manage their medicine.

  Recruiting at 2 sites Phase 4 Navamedic AB · Stockholm, Stockholm County and 4 other locations · NCT07839793

• Integrated Motor-Cognitive Training in Parkinson's Disease

  This study tests a combined motor and cognitive rehabilitation program to see if people with Parkinson’s disease can stick with it and show early signs of benefit.

  Recruiting University Hospital of Ferrara · Ferrara, FE · NCT07833748

• VIM0423 for Parkinson's Tremor in Adults Not Fully Controlled by Dopaminergic Therapy

  A Vima Therapeutics study tests whether the oral drug VIM0423 can reduce tremor in adults with Parkinson’s disease who still have tremor despite dopaminergic treatment.

  Recruiting at 4 sites Phase 2 Vima Therapeutics · Scottsdale, Arizona and 29 other locations · NCT07804615

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.